The global tulathromycin market size was valued at USD 977.8 million in 2023 and is projected to reach a value of USD 1,596.8 million by 2032, registering a CAGR of 5.6% during the forecast period (2024-2032). Tulathromycin market share is predicted to increase as the veterinary pharmaceutical business grows and meat consumption rises.
Tulathromycin is a macrolide antibiotic used in veterinary care. It belongs to the macrolide subclass known as triamilides. This antibiotic primarily treats and prevents respiratory infections in animals, specifically cattle and pigs. The market is impacted by worldwide trends in agriculture and animal husbandry, where demand for effective antibiotics remains high due to rising meat consumption. Regulatory factors such as withdrawal periods to ensure food safety and antimicrobial resistance shape the growth of the global market.
Additionally, as with other veterinary antibiotics, proper use and adherence to regulatory standards are critical to preserving the antibiotic's efficacy while addressing concerns about resistance. The market's dynamics are further influenced by continuous research and development efforts in the veterinary pharmaceutical sector, which attempt to introduce novel formulations and improve existing products.
Highlights
Cattle generates the most revenue in the market by animal type.
Population expansion, growing wages, and changing dietary choices have all contributed to a steady increase in worldwide meat consumption. As more people choose diets rich in meat and animal products, the need for intensive animal farming practices grows, perhaps contributing to an increased risk of respiratory infections in cattle. The Food and Agriculture Organization (FAO) predicts that meat production will reach 364 million tons in 2023, up slightly from 2022. According to the United Nations Food and Agriculture Organization, the pig is the world's most popular meat (36%), followed by poultry (33%), beef (24%), and goats/sheep (5%). With its massive and fast-urbanizing population, China has seen increased meat consumption. The country's transition to a more protein-rich diet has significantly increased cattle production, potentially increasing the danger of animal diseases. According to the OECD, China eats over 28% of global meat, including half of its pork. In 2021, China consumed about 100 million tons of beef, accounting for 27% of the worldwide total. This is double the amount consumed in the United States.
Furthermore, the OECD-FAO Agricultural Outlook 2023-2032 predicts that worldwide beef consumption will total 51 Mt over the following decade. The paper indicates that per capita consumption in Latin American countries will rise due to lower comparable pigmeat/beef pricing. The rising global meat consumption is a primary driver of demand for veterinary antibiotics like tulathromycin. The growing need to supply the protein requirements of a growing population drives the expansion of intensive animal farming practices, increasing the danger of respiratory infections in livestock and underlining the critical role of antibiotics in the health of these animals. This has an impact on the Tulathromycin Market trend.
Global regulatory organizations are becoming increasingly worried about the abuse and overuse of antibiotics, including tulathromycin, in both human and animal medicine. The rise of antibiotic-resistant bacteria is a serious public health concern, forcing regulatory authorities to tighten rules and control. Antibiotic resistance is being actively addressed by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). The "One Health" concept in the European Union seeks to combat antibiotic resistance by addressing its effects on human and animal health and the environment.
Additionally, the World Health Organization (WHO) reports that antibiotic resistance is a global hazard to public health. According to the paper, antibiotic resistance causes more extended hospital stays, higher medical costs, and a higher mortality rate. The World Health Organization highlights the necessity of appropriate antibiotic usage in humans and animals to combat resistance. As of August 8, 2023, 569,000 deaths had been attributed to bacterial AMR in all 35 nations in the WHO Region of the Americas. By 2050, AMR might kill 10 million people each year.
As a result, regulatory scrutiny and recommendations frequently restrict the use of specific antibiotics. The European Union (EU) has prohibited the routine use of antibiotics in farm animals since January 28, 2022. Since 2021, the EU has relaxed the ban on feeding processed animal protein (PAP) to non-ruminants like chicken and pork. Additionally, as of June 11, 2023, the FDA's order "Guidance for Industry #263" requires a prescription from a licensed veterinarian to acquire all over-the-counter (OTC) antibiotics for animal use. These antibiotics can only be obtained from a registered pharmacy or veterinarian.
Ongoing technological breakthroughs in veterinary medicine create considerable opportunities for innovation and growth in the tulathromycin market. Improvements in formulations, distribution systems, and overall product efficiency can improve tulathromycin's effectiveness while meeting growing industrial needs. The FDA announced additional features for the Veterinary Innovation Program (VIP) on September 15, 2023. The VIP Plus contains new tools to improve the FDA's approval process for VIP goods and aid in product development. Tulathromycin sustained-release formulations are one such example. Extended-release formulations can reduce the number of administrations, increase patient compliance, and give a more constant therapeutic impact. These advancements are consistent with the industry's desire for ease and efficacy.
Furthermore, incorporating nanotechnology into veterinary drug delivery systems is an additional opportunity for technical improvement. Nanoparticle-based formulations can increase tulathromycin bioavailability, potentially increasing therapeutic benefits and lowering dosage requirements. A study published in the Journal of Veterinary Pharmacology and Therapeutics looked into nanotechnology's possibility in the delivery of veterinary medicine. The study found that nanoparticle formulations can provide benefits such as sustained release, targeted administration, and increased drug solubility.
Thus, technological developments improve tulathromycin's efficacy and help it compete. Veterinarians and farmers are more likely to use formulations with better treatment effects, positively presenting technologically advanced tulathromycin products. Precision technologies in animal health, such as smart gadgets and sensors, can help to improve disease monitoring and treatment accuracy. This, in turn, may result in more targeted and effective tulathromycin use, along with the trend toward precision agriculture. Tulathromycin can be positioned as a modern and efficient option in the veterinary pharmaceutical environment through ongoing research and development into novel formulations, drug delivery technologies, and digital health solutions. Companies focusing on these improvements might acquire a competitive advantage and fulfill the market's changing expectations.
| Study Period | 2020-2032 | CAGR | 5.6% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD 977.8 million |
| Forecast Year | 2032 | Forecast Year Market Size | USD 1,596.8 million |
| Largest Market | Asia-Pacific | Fastest Growing Market | Europe |
The global tulathromycin market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.
Asia-Pacific is the most significant global tulathromycin market shareholder and is estimated to grow at a CAGR of 5.7% over the forecast period. Asia-Pacific is the second largest market for tulathromycin, with China and India each having a share of the pie. This is substantially attributed to the largest population of pigs and cattle. For example, China has over half of the world's pig population. China had the world's largest pig population in April 2023, with over 450 million pigs. In April 2023, China's breeding sow stock was 42.84 million, down 0.5% from the previous month but up 2.6% from the prior year.
Similarly, the Ministry of Agriculture and Rural Affairs said that China's live cattle stock was approximately 102.16 million at the end of 2022. In the first half of 2023, China produced 1.5 million more live cattle than in the same period in 2022. China's cattle production is predicted to expand by 1% in 2023, reaching 48.5 million head. Beef production is expected to increase by 8% in 2023.
Again, India is the largest country with the highest cattle population. As of 2023, India had 307.5 million cattle, including 194.2 million dairy cattle and 113.3 million water buffaloes. India has the world's most significant cow population. It has been observed that more farmers are diversifying their income-generating sources and shifting to dairy cultivation as a joint-pay source alongside conventional meat cultivation. As a result, tulathromycin is gaining popularity at a rapid pace.
Europe is anticipated to exhibit a CAGR of 5.8% over the forecast period. Various factors influence the European market, including the prevalence of respiratory disorders in cattle, regulatory considerations, and the overall dynamics of the veterinary pharmaceutical business. Tulathromycin is a new triamide antibiotic that has received European Union approval for treating and preventing respiratory illnesses in cows and pigs. As of April 2023, the European Union (EU) and the United States had the world's second-largest pig population, with over 134 million heads. However, in 2023, the EU's beef meat production is predicted to fall by 0.4pp to -2 % from the Spring 2023 forecast. The EU has also seen increased rivalry in high-value markets, resulting in a fall in exports.
However, According to 2023 research, sales of veterinary antibiotics in the European Union (EU) have dropped 53% from 2011. According to the research, sales plummeted from 161.2 mg/PCU in 2011 to 75.8 mg/PCU in 2022, the lowest ever reported.
North America holds a significant market share. Respiratory infections such as bovine respiratory disease (BRD) in cattle and swine respiratory diseases are common in North America. These diseases can harm animal health and productivity. The FDA approved the injectable Increxxa (tulathromycin) for use by cattle and swine producers and veterinarians in the United States in 2023. According to USDA's most recent Cattle report, the expected number of cattle and calves on January 1, 2023, is 89.3 million, a 3% decrease from the previous year.
Furthermore, the expected calving number for cows and heifers was 38.3 million, a 4% decrease from the previous year. The beef cow herd was estimated at 28.9 million heads, 4% lower than the 2022 prediction. The expected calf crop for 2022 is 34.5 million heads, 2% less than the 2021 crop. The cattle inventory in the United States is anticipated to fall further in 2023. According to the Cattle study, producers maintained 6% fewer replacement heifers for beef cow herds this year and forecast 5% fewer heifers to calve in 2023.
Latin America is an important player. Brazil, Mexico, Argentina, and Colombia have Latin America's largest economies and the most cattle and pig populations. Thanks to increased demand for dairy and meat products, Brazil currently accounts for more than half the regional cow population. The number of bovines in Brazil has increased substantially in recent years, and this estimate reflects the fact that more meat is being traded annually. The prevalence of BRD is high, expanding the LAMEA market in these regions.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global tulathromycin market is segmented based on animal type.
The market is further segmented by animal type into Cattle and swine.
Cattle generates the most revenue in the market.
Cattle
Tulathromycin is used in cattle to alleviate respiratory health issues common among bovine herds. Cattle, particularly those raised in intensive agriculture, are prone to respiratory disorders, including bovine respiratory disease (BRD), frequently connected with viral and bacterial infections. With its broad-spectrum activity against various infections, Tulathromycin is a vital antibiotic for treating and preventing BRD in cattle. Cattle farming, an essential component of meat and dairy production, depends on the herd's health and well-being. Tulathromycin's efficient use in cattle helps to preserve herd productivity, reduce economic losses caused by respiratory infections, and ensure the sustainability of cattle farming operations.
Furthermore, BRD remains a crucial driver in the tulathromycin industry. In the dairy business in the United States, respiratory illness continues to play a substantial role in calves' mortality because BRD affects survivorship. According to national surveys, respiratory disease is the primary cause of death in pre-weaned dairy cow calves, accounting for 44.8% of total calf mortality. Respiratory infections also cause 24.5% of pre-weaned dairy heifer calf fatalities.
Swine
Tulathromycin is an essential antibiotic in swine husbandry for treating respiratory problems in pig populations. Swine respiratory disorders caused by infections, such as Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae, can substantially influence herd health and productivity. Tulathromycin's efficacy against these bacteria makes it an essential antibiotic for managing and preventing swine respiratory illnesses. Given the increased intensity of pig farming and global demand for pork products, preserving swine herd respiratory health is critical. Tulathromycin adds to swine farming's health management approach, improving animal welfare and maintaining a sustainable and efficient pork-producing business.
Due to the pandemic, the entire world saw a financial slump. More than 70 nations went into a lockdown because of the rapid spread of the illnesses. The public authority acquainted severe conventions with controlling the spread of the contamination. The manufacturing units shut down, and the production decreased. The meat and dairy producers confronted bitter misfortunes. The interest in meat radically reduced during the initial phase of COVID-19 due to misguided judgments concerning the utilization of meat and meat items.
The meat producers dialed back because of the decrease in interest. This brought about the swarming of animals on the farms. The farm owners needed more assets to pay for the prescriptions and treatment of impacted livestock, which severely affected the worldwide tulathromycin market. During this period, Zoetis saw a decay of 15% in the income produced from the offer of the medication.
